Page last updated: 2024-11-05

lidocaine hydrochloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lidocaine hydrochloride monohydrate : The monohydrate form of lidocaine hydrochloride. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

lidocaine hydrochloride : The anhydrous form of the hydrochloride salt of lidocaine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16219577
CHEMBL ID1200409
CHEBI ID60791
SCHEMBL ID29128
MeSH IDM0012489
PubMed CID6314
CHEMBL ID541521
CHEBI ID50512
MeSH IDM0012489

Synonyms (207)

Synonym
xylocaine hydrochloride
lidocaine hydrochloride monohydrate
zingo
acetamide, 2-(diethylamino)-n-(2,6-dimethylphenyl)-, monohydrochloride, monohydrate
lignocaine hydrochloride
2-(diethylamino)-2',6'-acetoxylidide monohydrochloride monohydrate
lidopen
dolicaine
2',6'-acetoxylidide, 2-(diethylamino)-, hydrochloride, hydrate
diethylaminoacet-2,6-xylidide hydrochloride monohydrate
smr000653485
MLS001076361
anestacon
lidocaton
lidocaine hydrochloride monohydrate, solid
dalcaine
lignocaine (as hydrochloride)
lidocaine hydrochloride usp
lidocaini hydrochloridum
CHEMBL1200409
chebi:60791 ,
D08127
6108-05-0
zingo (tn)
lidocaine (tn)
AKOS015995687
zingo tm
v13007z41a ,
lidocaine hydrochloride [usp:ban:jan]
lidocaine hcl hydrate
unii-v13007z41a
akten
xylocaine hydrochloride monohydrate
lidocaine hydrochloride hydrate
lidocaine hcl [inci]
lidocaine hydrochloride component of embolex
embolex component lidocaine hydrochloride
iontocaine component lidocaine hydrochloride
lidocaine hydrochloride monohydrate [mart.]
lidocaine hydrochloride [usp-rs]
lidocaine hydrochloride component of lidosite topical system kit
lidocaine hydrochloride [usp monograph]
lidocaine hydrochloride monohydrate [ep monograph]
lignospan forte component lidocaine hydrochloride
lidocaine hydrochloride [who-ip]
hbn-1 component lidocaine hydrochloride
lidocaine hydrochloride component of duocaine
lidocaine hydrochloride [orange book]
lidocaine hydrochloride [ep impurity]
lidocaine hydrochloride component of hbn-1
lidocaine hydrochloride [green book]
lidocaine hydrochloride [mi]
duocaine component lidocaine hydrochloride
lidocaine hydrochloride [vandf]
lidocaini hydrochloridum [who-ip latin]
octocaine component lidocaine hydrochloride
lidosite topical system kit component lidocaine hydrochloride
lidocaine hydrochloride component of octocaine
lidocaine hydrochloride monohydrate [who-dd]
lidocaine hydrochloride component of lignospan forte
lidocaine hydrochloride component of iontocaine
SCHEMBL29128
KS-5057
YECIFGHRMFEPJK-UHFFFAOYSA-N
2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide hydrochloride hydrate
linocaine hydrochloride
DTXSID80209953
lidocaine hydrochloride, united states pharmacopeia (usp) reference standard
lidocaine hydrochloride, european pharmacopoeia (ep) reference standard
lidocaine hydrochloride, pharmaceutical secondary standard; certified reference material
lidocaine hydrochloride monohydrate; lidocaine hydrochloride monohydrate; cci 1873a
lidocaine hydrochloride, british pharmacopoeia (bp) reference standard
Q27128594
BCP13499
2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;hydrate;hydrochloride
lidocaine (hydrochloride hydrate)
H11982
CS-0021579
HY-B0185B
lidocaine hcl
isicaine hydrochloride
einecs 200-803-8
omega-diethylamino-2,6-dimethylacetanilide hydrochloride
laryng-o-jet
xylestesin hydrochloride
leostesin hydrochloride
2-diethylamino-2',6'-acetoxylidide hydrochloride
lidocaine hydrochloride anhydrous
lidothesin
n-(diethylaminoacetyl)-2,6-dimethylaniline hydrochloride
lidocaine viscous
lidothesin hydrochloride
xylocaine 1.5% w/ dextrose 7.5%
2',6'-acetoxylidide, 2-(diethylamino)-, monohydrochloride
laryngotracheal anesthesia kit
laryng-o-jet kit
xycaine hydrochloride
pediatric lta kit
xylocitin hydrochloride
duncaine hydrochloride
xylocaine preservative free
v 262
2',6'-acetoxylidide, 2-(diethylamino)-, hydrochloride
gravocain hydrochloride
acetamide, 2-(diethylamino)-n-(2,6-dimethylphenyl)-, monohydrochloride
anestacon hydrochloride
rucaina hydrochloride
s 202
alpha-diethylamino-2,6-acetoxylidine hydrochloride
xylocaine 5% w/ glucose 7.5%
lta ii kit
xylotox hydrochloride
lidocain hydrochloride
xylocaine 4% preservative free
xilina hydrochloride
MLS000069665 ,
EU-0100669
xylocaine viscous
PRESTWICK_296
lidoca ne hydrochloride
lidocaine hydrochloride
73-78-9
lidocaine monohydrochloride
xyloneural
lidocaine hydrochloride (jan/usp)
D02086
dalcaine (tn)
NCGC00094030-02
NCGC00094030-03
smr000058468
SPECTRUM1500689
NCGC00094030-05
NCGC00094030-01
NCGC00094030-04
CHEBI:50512 ,
AC-11712
L 5647
CHEMBL541521
anhydrous lidocaine hydrochloride
nsc-757420
HMS1921C22
HMS1568I21
2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide hydrochloride
A837924
2-(diethylamino)-n-(2,6-dimethylphenyl)ethanamide hydrochloride
lidocaine hydrochloride 0.2% in dextrose 5% in plastic container
acetamide, 2-(diethylamino)-n-(2,6-dimethylphenyl)-, hydrochloride (1:1)
unii-ec2cnf7xfp
lidocaine hydrochloride 0.2% in dextrose 5%
ec2cnf7xfp ,
lidocaine hydrochloride preservative free in plastic container
lidocaine hydrochloride in plastic container
glydo
lidocaine hydrochloride 0.8% in dextrose 5% in plastic container
alphacaine hydrochloride
lidocaine hydrochloride 0.4% and dextrose 5% in plastic container
lidocaine hydrochloride viscous
lidocaine hydrochloride 0.1% and dextrose 5% in plastic container
nsc 757420
lidocaine hydrochloride 5% and dextrose 7.5%
lidocaine hydrochloride preservative free
lidocaine hydrochloride 0.4% in dextrose 5% in plastic container
lidocaine hydrochloride 0.8% and dextrose 5% in plastic container
lidocaine hydrochloride 0.2% and dextrose 5% in plastic container
lidocaine hydrochloride 0.4% in dextrose 5%
nsc757420
pharmakon1600-01500689
S4667
CCG-39281
LP00669
2-(diethylamino)-2',6'-acetoxylidide monohydrochloride
lidocaine hydrochloride [who-dd]
lidocaine hydrochloride [jan]
lidocaine hydrochloride anhydrous [mart.]
AKOS015889456
IYBQHJMYDGVZRY-UHFFFAOYSA-N
NCGC00261354-01
tox21_500669
CS-3888
DTXSID4058782
Q-201304
HY-B0185A
lidocaine (hydrochloride)
OPERA_ID_351
EN300-7398170
SR-01000000189-3
sr-01000000189
SR-01000000189-9
A16132
AS-35171
Q27122094
lignocaine hydrochloride pound>>lidocaine hcl
BCP30473
SB19119
73-78-9 (hcl); 6108-05-0 (monohydrate)
2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide;hydrochloride
GLXC-26369
lidocaine hydrochloride monohydrate (mart.)
xylocaine 5% w/glucose 7.5%
lidocaine hydrochloride monohydrate (ep monograph)
lidocaine hydrochloride (usp monograph)
lidocaine hydrochloride (usp-rs)
lidocaine hydrochloride (ep impurity)
lidocaine hydrochloride anhydrous (mart.)
xylocaine dental
2-(diethylamino)-n-(2,6-dimethylphenyl)acetamide monohydrochloride
xylocaine 1.5% w/dextrose 7.5%
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
local anaestheticAny member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block.
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
local anaestheticAny member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block.
anti-arrhythmia drugA drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
hydrateAn addition compound that contains water in weak chemical combination with another compound.
hydrochlorideA salt formally resulting from the reaction of hydrochloric acid with an organic base.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency29.09290.00419.984825.9290AID504444
Microtubule-associated protein tauHomo sapiens (human)Potency0.14130.180013.557439.8107AID1468
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00320.540617.639296.1227AID2364; AID2528
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency56.23410.036619.637650.1187AID1466; AID2242
lamin isoform A-delta10Homo sapiens (human)Potency2.39150.891312.067628.1838AID1487
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency56.23413.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency56.23413.548118.039535.4813AID1466
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2 Rattus norvegicus (Norway rat)KmH2,881.00003.80003.80003.8000AID1210873; AID1210875
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (75)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1210873Activity of rat recombinant CYP1A2 expressed in Escherichia coli assessed as enzyme-mediated N-deethylation incubated for 5 mins prior to NADPH addition measured after 15 mins by Michaelis-Menten equation analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID1210872Drug metabolism in human liver microsomes assessed as enzyme-mediated N-deethylation incubated for 5 mins prior to NADPH addition measured after 15 mins by Michaelis-Menten equation analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID1210875Activity of rat recombinant CYP1A2 expressed in Escherichia coli assessed as enzyme-mediated N-deethylation incubated for 5 mins prior to NADPH addition measured after 15 mins by Michaelis-Menten equation analysis in presence of BSA2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID1210874Drug metabolism in human liver microsomes assessed as enzyme-mediated N-deethylation incubated for 5 mins prior to NADPH addition measured after 15 mins by Michaelis-Menten equation analysis in presence of BSA2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID1210868Fraction unbound in human liver microsomes by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID1210866Binding affinity to rat recombinant CYP1A2 expressed in Escherichia coli assessed as fraction unbound by equilibrium dialysis method2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID1210885Drug metabolism in human liver microsomes assessed as retention time at 25 to 8000 uM incubated for 5 mins prior to NADPH addition measured after 25 mins by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID1210869Fraction unbound in human liver microsomes by equilibrium dialysis method in presence of BSA2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID1210881Intrinsic clearance in healthy human at 1 to 1.5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID1210882Hepatic clearance in healthy human at 1 to 1.5 mg/kg, iv2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID1210887Stability of the compound assessed as retention time by HPLC analysis2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Effect of albumin on human liver microsomal and recombinant CYP1A2 activities: impact on in vitro-in vivo extrapolation of drug clearance.
AID1130795Toxicity in Swiss albino mouse assessed as induction of convulsions at 100 mg/kg, sc relative to control1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 1. Primary alpha-amino anilides.
AID60249Percent of normal beats after 5 mg/kg given over 5 min by i.v. infusion.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of alpha-[(diarylmethoxy)methyl]-1-piperidineethanols.
AID1130793Antiarrhythmic activity in Swiss albino mouse assessed as protection against chloroform-induced fibrillation at 100 mg/kg, sc relative to control1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 1. Primary alpha-amino anilides.
AID1130792Antiarrhythmic activity in coronary ligated dog assessed as reduction of ventricular ectopic beats to <5% of total ventricular beats at 0.5 mg/kg, iv measured for 5 mins relative to control1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 1. Primary alpha-amino anilides.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1130803Toxicity in iv dosed coronary ligated dog assessed as concentration required to cause convulsions1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 1. Primary alpha-amino anilides.
AID1130802Antiarrhythmic activity in iv dosed coronary ligated dog assessed as concentration required to reduce ventricular ectopic beats to <5% of total ventricular beats measured for 5 mins1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 1. Primary alpha-amino anilides.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID58619Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing for conversion to sinus rhythm.1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Antiarrhythmic activity of amitriptyline analogues in conscious dogs after myocardial infarction: cyproheptadinium methiodide.
AID307551Anesthetic activity in toad sciatic nerves assessed as sciatic nerve block activity relative to Lidocaine2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and local anesthetic activity of fluoro-substituted imipramine and its analogues.
AID1130800Antiarrhythmic activity in coronary ligated dog assessed as reduction of mean arterial blood pressure at 0.5 mg/kg, iv measured for 5 mins relative to control1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 1. Primary alpha-amino anilides.
AID60247Percent of normal beats 1 hr after 5 mg/kg given over 5 min by i.v. infusion.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of alpha-[(diarylmethoxy)methyl]-1-piperidineethanols.
AID1130796Toxicity in Swiss albino mouse assessed as induction of loss of righting reflex at 100 mg/kg, sc relative to control1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 1. Primary alpha-amino anilides.
AID1130797Antiarrhythmic activity in sc dosed Swiss albino mouse assessed as protection against chloroform-induced fibrillation relative to control1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 1. Primary alpha-amino anilides.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID60248Percent of normal beats 20 min after 5 mg/kg given over 5 min by i.v. infusion.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of alpha-[(diarylmethoxy)methyl]-1-piperidineethanols.
AID1130801Antiarrhythmic activity in coronary ligated dog assessed as reduction of ventricular rates at 0.5 mg/kg, iv measured for 5 mins relative to control1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 1. Primary alpha-amino anilides.
AID57671Activity rating following 100.5 mg/kg i.v. administration.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Synthesis and antiarrhythmic activity of alpha-[(diarylmethoxy)methyl]-1-piperidineethanols.
AID58617Evaluated for the antiarrhythmic activity in conscious dogs after myocardial infarction by observing 50% reduction in ectopic rate.. 1980Journal of medicinal chemistry, Nov, Volume: 23, Issue:11
Antiarrhythmic activity of amitriptyline analogues in conscious dogs after myocardial infarction: cyproheptadinium methiodide.
AID307550Anesthetic activity in toad sciatic nerves assessed as latent period of sciatic nerve block2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and local anesthetic activity of fluoro-substituted imipramine and its analogues.
AID307549Anesthetic activity in toad sciatic nerves assessed as sciatic nerve block activity2007Bioorganic & medicinal chemistry letters, Jul-01, Volume: 17, Issue:13
Synthesis and local anesthetic activity of fluoro-substituted imipramine and its analogues.
AID1130794Toxicity in Swiss albino mouse assessed as induction of ataxia at 100 mg/kg, sc relative to control1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
New antiarrhythmic agents. 1. Primary alpha-amino anilides.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (10.53)18.7374
1990's1 (5.26)18.2507
2000's4 (21.05)29.6817
2010's10 (52.63)24.3611
2020's2 (10.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 79.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index79.41 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index5.20 (4.65)
Search Engine Demand Index135.92 (26.88)
Search Engine Supply Index2.04 (0.95)

This Compound (79.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Reviews1 (5.56%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
Other17 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]